Contract HHSN302201300041P
National Disease Research Interchange · Department Of Health And Human Services · February 21, 2013
National Disease Research Interchange was awarded a federal contract by Department Of Health And Human Services (National Institutes Of Health) on February 21, 2013 for $8,000 of work in biological product (except diagnostic) manufacturing. Performance is in Philadelphia, PA. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 10, 2018.
Contract details
- PIID
- HHSN302201300041P
- Award type
- Purchase Order
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Competed Under Sap
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Philadelphia, PA
- First action
- February 21, 2013
- Latest action
- July 10, 2018
Description
NATL DISEASE RESCH INTERCHANGE:1106823 [13-003041]
Modification timeline
-
July 10, 2018Mod 2$-52
-
July 9, 2018Mod 1$0
-
February 21, 2013Base award$7.7K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Bio-Rad Laboratories, Inc. | Department Of Health And Human Services | March 31, 2026 | $20.6K |
| Georgia Tech Research Corp | Department Of Health And Human Services | March 28, 2026 | $145.8K |
| Seqirus Inc | Department Of Health And Human Services | March 25, 2026 | $23.7K |
| Seqirus Inc | Department Of Health And Human Services | March 24, 2026 | $0 |
| Battelle Memorial Institute | Department Of Health And Human Services | March 19, 2026 | $2.80M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 19, 2026 | $53.21M |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract HHSN302201300041P?
Contract HHSN302201300041P is a federal contract awarded to National Disease Research Interchange by Department Of Health And Human Services on February 21, 2013 for $8,000 of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 2 times since the base award.
Who won contract HHSN302201300041P?
National Disease Research Interchange won contract HHSN302201300041P from Department Of Health And Human Services.
How much is contract HHSN302201300041P worth?
Contract HHSN302201300041P has obligated $8,000 to date.